Asymmetric Di-Methyl Histone H3 (Arg2) (E7W7S) Rabbit mAb #33725
- WB
Supporting Data
| REACTIVITY | H M R Mk |
| SENSITIVITY | Endogenous |
| MW (kDa) | 17 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
- Mk-Monkey
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
Asymmetric Di-Methyl Histone H3 (Arg2) (E7W7S) Rabbit mAb recognizes endogenous levels of total H3 protein only when asymmetrically di-methylated at Arg2. This antibody does not cross-react with histone H3 when mono-methylated or symmetrically di-methylated at Arg2. This antibody does not cross-react with any other known methylated arginine residues on histone H3.
Species Reactivity:
Human, Mouse, Rat, Monkey
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human histone H3 protein in which Arg2 is asymmetrically di-methylated.
Background
The nucleosome is the primary chromatin building block and consists of DNA wrapped around an octamer made of paired histone proteins H2A, H2B, H3, and H4. Chromatin remodeling plays a critical role in the regulation of various nuclear activities, including transcription. Histone proteins are targets of post-translational modification, including acetylation, phosphorylation, ubiquitination, and methylation. Modified histone residues are recognized and bound by chromatin modifiers and the transcription machinery to regulate gene expression (1-4). Protein arginine methyltransferases (PRMTs) methylate histone proteins at arginine residues to generate mono-methylated, symmetrically di-methylated, or asymmetrically di-methylated proteins. Asymmetrically di-methylated arginine residues are found on histone H3 (Arg2, 8, 17, 26, and 42), histone H4 (Arg3), and histone H2A (Arg3) proteins. Asymmetric methylation is carried out by type 1 PRMTs, which include PRMT1, PRMT2, PRMT4/CARM1, and PRMT6. These modifications are often associated with actively transcribed genes. Symmetric di-methylation of arginine residues are found on histone H3 (Arg2 and 8), histones H4 (Arg3), and H2A (Arg3). Symmetrically di-methylated histone arginine residues are generated by type II transferases PRMT5 and PRMT7, and are often associated with transcription repression (5-9). Arginine residues can also be deiminated by a peptidyl arginine deiminase (PADI) to form the non-coded amino acid citrulline. Conversion of arginine to citrulline prevents methylation of this residue and is thought to regulate histone arginine methylation levels (10-13).
- Swygert, S.G. and Peterson, C.L. (2014) Biochim Biophys Acta, 728-36.
- Zentner, G.E. and Henikoff, S. (2013) Nat Struct Mol Biol 20, 259-66.
- Rothbart, S.B. and Strahl, B.D. (2014) Biochim Biophys Acta, 627-43.
- Gayatri, S. and Bedford, M.T. (2014) Biochim Biophys Acta, 702-10.
- Wysocka, J. et al. (2006) Front Biosci 11, 344-55.
- Di Lorenzo, A. and Bedford, M.T. (2011) FEBS Lett 585, 2024-31.
- Yang, Y. and Bedford, M.T. (2013) Nat Rev Cancer 13, 37-50.
- Molina-Serrano, D. et al. (2013) Biochem Soc Trans 41, 751-9.
- Casadio, F. et al. (2013) Proc Natl Acad Sci USA 110, 14894-9.
- Wang, Y. et al. (2004) Science 306, 279-83.
- Cuthbert, G.L. et al. (2004) Cell 118, 545-53.
- Zhang, X. et al. (2012) Proc Natl Acad Sci USA 109, 13331-6.
- Christophorou, M.A. et al. (2014) Nature 507, 104-8.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.